A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01

BACKGROUND: Gemcitabine and cisplatin has limited benefit as treatment for advanced biliary tract cancer (BTC). The addition of an anti‐programmed death receptor (PD‐1)/PD‐ligand (L1) antibody to either systemic chemotherapy or anti‐cytotoxic T‐lymphocyte‐associated protein 4 (CTLA4) antibody has sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahai, Vaibhav, Griffith, Kent A., Beg, Muhammad S., Shaib, Walid L., Mahalingam, Devalingam, Zhen, David B., Deming, Dustin A., Zalupski, Mark M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540241/
https://www.ncbi.nlm.nih.gov/pubmed/35895381
http://dx.doi.org/10.1002/cncr.34394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540241/
https://www.ncbi.nlm.nih.gov/pubmed/35895381
http://dx.doi.org/10.1002/cncr.34394

Ejemplares similares